Remedy Robotics raises $62M Series B for AI-enabled endovascular robot

Nov 16, 2026
DCVC led the round; the money funds a pivotal trial with the University of California and work toward FDA approval.

Remedy Robotics, which develops robotic systems for cardiovascular care and endovascular procedures, has raised $62 million in Series B funding led by DCVC, the company said in a press release. New investors include UC Investments, the University of California's investment office, Skip Capital and Australian pension fund Hostplus, and existing investors including Tony Fadell's Build Collective and Blackbird added to their stakes.

Remedy is finalising its N1 System, an AI-enabled robotic platform that uses machine learning to analyse preoperative imaging, simulate cases in advance and complete entire endovascular procedures robotically, on site, remotely or autonomously. The company says it works with more than 100 hospitals and completed the world's first remote neurointerventional procedures with the system in October 2025.

The money will fund a planned pivotal clinical trial with the University of California, work toward FDA approval for neurovascular intervention, and deployment of prototype N1 Systems with clinical partners including SVIN Mission Thrombectomy and the Australian Stroke Alliance. "This funding will allow us to accelerate toward deployment of our N1 System," said CEO and co-founder Dr. David Bell.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Robotics Brief, Life AI Weekly or Daily AI Brief.

Free newsletter

Robotics Brief

Weekly coverage of AI-driven robotics advances in industrial automation, autonomous vehicles, and robotic systems.

Market report

2025 Generative AI in Professional Services Report

Thomson Reuters

This report by Thomson Reuters explores the integration and impact of generative AI technologies, such as ChatGPT and Microsoft Copilot, within the professional services sector. It highlights the growing adoption of GenAI tools across industries like legal, tax, accounting, and government, and discusses the challenges and opportunities these technologies present. The report also examines professionals' perceptions of GenAI and the need for strategic integration to maximize its value.

Read more
Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.